TROG 15.01 (SPARK)

Primary sponsor: University of Sydney
Collaborating group: Trans Tasman Radiation Oncology Group (TROG)

Title

Stereotactic Prostate Adaptive Radiotherapy utilising KIM (Kilovoltage Intrafraction Monitoring)

Summary

Most linear accelerators used to treat cancer patients today are equipped with fixed X-ray imagers which are typically used to take images of a tumour before a patient receives radiotherapy. A new technology, known as Kilovoltage Intrafraction Monitoring (KIM), has recently emerged which allows images of a tumour to be taken in real-time while the treatment is occurring. The advantage of KIM is that it enables strategies such as patient shifting or beam shifting during treatment which could potentially improve the accuracy of the treatment and reduce the patient’s side effects. In addition, due to the accuracy of KIM in targeting tumours, the number of treatment sessions this group of patients will require will be reduced to five as opposed to the 40 sessions required using more conventional treatment methods.

The SPARK trial is testing the use of KIM in prostate cancer patients being treated with Stereotactic Prostate Adaptive Radiotherapy. The researchers expect this trial to result in better targeted prostate cancer patient outcomes with lower toxicity. The potential application of KIM to other tumour sites will pave the way for additional trials with Australasian radiation oncology leading the world.

Final Accrual 

49

Trial Status

Closed to accrual, March 2018

Trial chairpersons

Professor Paul Keall, University of Sydney, NSW
Associate Professor Jarad Martin, Calvary Mater Newcastle, NSW

Trial contact

Brita Lehmann
TROG Trial Coordinating Centre
Phone: +61 2 4014 3912
Email: spark@trog.com.au

Further information

TROG trial 15.01 on Australian Cancer Trials website

Trial resources for TROG members

TROG 15.01 SPARK member page